DEF 14A: Liquidia Corporation Seeks Stockholder Approval for Director Elections, Share Increase, and Executive Compensation

Liquidia Corporation's upcoming annual meeting on June 20, 2024, will address director elections, an increase in authorized common stock, auditor ratification, and advisory votes on executive compensation.

Summary

• Liquidia Corporation is holding its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, at 4:30 p.m. Eastern Time.
• Stockholders will vote on electing three Class III directors, approving an amendment to increase authorized common stock from 100,000,000 to 115,000,000 shares, ratifying PricewaterhouseCoopers LLP as the independent auditor, and advisory votes on executive compensation.
• The record date for voting is April 26, 2024, with 76,382,718 shares outstanding and entitled to vote.
• The company anticipates mailing the Notice Regarding Internet Availability of Proxy Materials on or about May 6, 2024.
• The Board recommends voting FOR all director nominees, the charter amendment, auditor ratification, and the advisory vote on executive compensation, as well as a frequency of ONE YEAR for future advisory votes on executive compensation.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral to slightly positive tone. The company is seeking approval for routine matters and highlighting its commitment to corporate governance best practices.

Positives

• The Board is actively engaged in corporate governance, with regular meetings and committees overseeing key areas such as audit, compensation, and nominations.
• The company is providing stockholders with convenient access to proxy materials online, reducing paper usage and costs.
• The Board recommends a frequency of one year for future advisory votes on executive compensation, indicating a commitment to regular stockholder input.
• The company has adopted a Clawback Policy in accordance with Nasdaq listing standards.

Negatives

• Paul Manning attended fewer than 75% of the aggregate of all meetings of the Board held during the fiscal year ended December 31, 2023.
• Without an increase in the number of authorized shares of common stock, we may be constrained in our ability to raise capital in a timely fashion or at all and may be unable to complete our clinical programs, commercialize our products, or conduct important business activities, which could adversely affect our financial performance and growth.

Risks

• Failure to approve the increase in authorized shares could limit the company's ability to raise capital and pursue strategic opportunities.
• The issuance of additional shares of common stock may decrease the relative percentage of equity ownership of our existing stockholders, thereby diluting the voting power of their common stock.
• A takeover may be beneficial to independent stockholders because, among other reasons, a potential suitor may offer such stockholders a premium for their shares of common stock as compared to the then-existing market price.

Future Outlook

The company intends to announce preliminary voting results at the Annual Meeting and publish final results in a Current Report on Form 8-K within four business days following the meeting.

Management Comments

• On behalf of the Board of Directors, I thank you for your continued support of Liquidia Corporation.
• The Board determined that election of each of the nominees for director named above is advisable and in the best interests of Liquidia and its stockholders.
• The Board determined that approval of the Charter Amendment Proposal is advisable and in the best interests of Liquidia and its stockholders.
• The Board determined that ratification of the Audit Committees appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2024 is advisable and in the best interests of the Company and its stockholders.
• The Board determined that the approval, on an advisory basis, of the compensation of our named executive officers is advisable and in the best interests of the Company and its stockholders.
• The Board determined that the approval, on an advisory basis, to have future advisory votes on executive compensation every year is advisable and in the best interests of the Company and its stockholders.

Industry Context

The proxy statement reflects standard corporate governance practices for publicly traded companies, including director elections, auditor ratification, and executive compensation disclosures. The proposed increase in authorized shares is a common measure to provide flexibility for future financing and strategic transactions.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and equity awards, is generally consistent with industry practices for similarly sized biotechnology and pharmaceutical companies.
• The virtual annual meeting format aligns with a growing trend among public companies to enhance accessibility and reduce costs.
• The company's commitment to board diversity and the inclusion of independent directors on key committees reflect best practices in corporate governance.
• The company's clawback policy is in line with Nasdaq listing standards and aims to ensure accountability for financial reporting errors.

Related Party Transactions

• Caligan, our largest stockholder and an affiliate of David Johnson, a member of our Board, and Paul B. Manning, a member of our Board, participated in the 2022 Offering and purchased shares of our common stock in an aggregate amount of approximately $11 million at the public offering price per share and on the same terms as the other purchasers in the Offering.
• Caligan, our largest stockholder and an affiliate of David Johnson, a member of our Board, and Paul B. Manning, a member of our Board, participated in the 2023 Offering and purchased shares of our common stock in an aggregate amount of approximately $10 million at the public offering price per share and on the same terms as the other purchasers in the Offering.
• On December 12, 2023, we entered into a common stock purchase agreement with Roger Jeffs, our Chief Executive Officer, in connection with the private sale of 139,665 unregistered shares of our common stock, in a private placement at a purchase price of $7.16 per share for an aggregate investment amount of approximately $1 million.

Stakeholder Impact

• Approval of the proposals will enable the company to pursue its strategic objectives and enhance stockholder value.
• The election of qualified directors will ensure effective oversight and governance of the company.
• The advisory votes on executive compensation provide stockholders with an opportunity to express their views on the company's pay practices.
• The company's commitment to transparency and communication with stockholders fosters trust and confidence.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting on June 20, 2024, to address the listed proposals.
• The company will announce preliminary voting results at the Annual Meeting and publish final results in a Current Report on Form 8-K.

Key Dates

Keywords

proxy statement, annual meeting, directors, executive compensation, authorized shares, corporate governance, stockholders, liquidation corporation, voting